Lunai Bioworks (NASDAQ:LNAI) Announces Quarterly Earnings Results

Lunai Bioworks (NASDAQ:LNAI) issued its quarterly earnings data on Friday. The company reported $0.13 earnings per share (EPS) for the quarter, Zacks reports.

Lunai Bioworks Trading Up 2.9%

Shares of LNAI traded up $0.03 during mid-day trading on Friday, reaching $1.06. The stock had a trading volume of 593,767 shares, compared to its average volume of 8,996,835. The firm has a market capitalization of $24.57 million, a P/E ratio of -0.14 and a beta of 0.31. Lunai Bioworks has a 52-week low of $0.81 and a 52-week high of $21.00.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Weiss Ratings started coverage on Lunai Bioworks in a report on Wednesday, October 8th. They issued a “sell (e+)” rating for the company. Wall Street Zen lowered Lunai Bioworks to a “strong sell” rating in a research report on Friday, October 3rd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

About Lunai Bioworks

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase.